NPCE - NASDAQ
NeuroPace, Inc.
$16.65
+2.2%NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
At a Glance
Live Snapshotnpce
Cash and Short Term Investments
Last Annual Value
61.06M
3-Year CAGR
-8%
5-Year CAGR
10%
10-Year CAGR
28%
NeuroPace, Inc. Competitors Analysis of Cash and Short Term Investments
| Company | Cash and Short Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
NeuroPace, Inc. NASDAQ:NPCE | 61.06M | -2.8% | -12.0% | N/A | |
 Delcath Systems, Inc. NASDAQ:DCTH | 91.04M | 41.0% | 31.9% | 35.4% | |
 Senseonics Holdings, Inc. NASDAQ:SENS | 94.03M | -4.9% | -6.3% | 16.5% | |
 CVRx, Inc. NASDAQ:CVRX | 75.71M | -5.8% | -11.8% | N/A | |
 Aldeyra Therapeutics, Inc. NASDAQ:ALDX | 70.04M | -21.1% | -21.1% | 10.9% | |
 RxSight, Inc. NASDAQ:RXST | 228.13M | 21.5% | 7.4% | N/A | |
 Genelux Corporation NASDAQ:GNLX | 14.60M | -14.3% | 26.6% | N/A | |
 908 Devices Inc. NASDAQ:MASS | 112.97M | -8.1% | -12.8% | N/A | |
 Cerus Corporation NASDAQ:CERS | 82.88M | 8.0% | -8.5% | 1.5% | |
 Sight Sciences, Inc. NASDAQ:SGHT | 91.97M | -12.7% | -18.8% | N/A |
NeuroPace, Inc. Fair Value Envelope
Related Guides
Continue your NPCE research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.